[1] [1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-49.

[2] [2] VALDERRAMA-TREVIO A I, BARRERA-MERA B, CEBALLOS-VILLALVA J C, et al. Hepatic metastasis from colorectal cancer[J]. Euroasian J Hepato-gastroenterol, 2017, 7(2): 166-175.

[3] [3] PRABHU A, MISHRA D, BRANDL A, et al. Gastric cancer with peritoneal metastasis-a comprehensive review of current intraperitoneal treatment modalities[J]. Front Oncol, 2022, 12: 864647.

[4] [4] HODGE C, BADGWELL B D. Palliation of malignant ascites[J]. J Surg Oncol, 2019, 120(1): 67-73.

[5] [5] VAN STEIN R M, AALBERS A G J, SONKE G S, et al. Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer: a review[J]. JAMA Oncology, 2021, 7(8): 1231-1238.

[7] [7] STUKAN M. Drainage of malignant ascites: patient selection and perspectives[J]. Cancer Manag Res, 2017, 9: 115-130.

[8] [8] BA M, CUI S, LONG H, et al. Safety and effectiveness of high-precision hyperthermic intraperitoneal perfusion chemotherapy in peritoneal carcinomatosis: a real-world study[J]. Front Oncol, 2021, 11: 674915.

[9] [9] CEELEN W, HELENA B, GABRIELLE V R, et al. Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion[J]. Expert Opin Drug Del, 2020, 17(4): 511-522.

[10] [10] GUCHELAAR N A D, NOORDMAN B J, KOOLEN S L W, et al. Intraperitoneal chemotherapy for unre-sectable peritoneal surface malignancies[J]. Drugs, 2023, 83(2): 159-180.

[11] [11] JI Z, SUN J, WU H, et al. Assessment of hyperthermic intraperitoneal chemotherapy to eradicate intraperitoneal free cancer cells[J]. Transl Oncol, 2016, 9(1): 18-24.

[12] [12] NI X, WU P, WU J, et al. Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites[J]. Oncol Lett, 2017, 14(2): 1691-1696.

[13] [13] JIAO J, LI C, YU G, et al. Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites[J]. World J Surg Oncol, 2020, 18(1): 180.

[15] [15] LI Y, LIU B, YANG F, et al. Lobaplatin induces BGC-823 human gastric carcinoma cell apoptosis via ROS- mitochondrial apoptotic pathway and impairs cell migration and invasion[J]. Biomed Pharmacother, 2016, 83: 1239-1246.

[16] [16] YU J, LI S, QI J, et al. Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells[J]. Cell Death Dis, 2019, 10(3): 193.

[17] [17] MAURICI C E, COLENBIER R, WYLLEMAN B, et al. Hyperthermia enhances efficacy of chemotherapeutic agents in pancreatic cancer cell lines[J]. Biomolecules, 2022, 12(5): 651.

[18] [18] DORIGO O, BEREK J S. Personalizing CA125 levels for ovarian cancer screening[J]. Cancer Prev Res (Phila), 2011, 4(9): 1356-1359.

[19] [19] WINARNO G N A, HIDAYAT Y M, SOETOPO S, et al. The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers[J]. BMC Research Notes, 2020, 13(1): 346.

[20] [20] WANG Q, FENG X, LIU X, et al. Prognostic value of elevated pre-treatment serum CA-125 in epithelial ovarian cancer: a meta-analysis[J]. Front Oncol, 2022, 12: 868061.

[21] [21] PIATEK S, PANEK G, LEWANDOWSKI Z, et al. Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer[J]. J Ovarian Res, 2020, 13(1): 102.

[22] [22] DOCHEZ V, CAILLON H, VAUCEL E, et al. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review[J]. J Ovarian Res, 2019, 12(1): 28.

[23] [23] ZHONG Y, KANG W, HU H, et al. Lobaplatin-based prophylactic hyperthermic intraperitoneal chemotherapy for T4 gastric cancer patients: A retrospective clinical study[J]. Front Oncol, 2023, 13: 995618.

[25] [25] LIU C, SHAN X, LIU Z. Analysis of adverse reactions and clinical rational drug use of antitumor drug paclitaxel[J]. Minerva medica, 2023, 8(4): 114.